Equities research analysts predict that AMETEK, Inc. (NYSE:AME) will announce sales of $1.18 billion for the current quarter, according to Zacks Investment Research . Six analysts have made estimates for AMETEK's earnings, with estimates ranging from $1.17 billion to $1.19 billion. AMETEK reported sales of $1.08 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.3%. The company is scheduled to report its next earnings report on Thursday, November 1st.
According to Zacks, analysts expect that AMETEK will report full-year sales of $4.77 billion for the current fiscal year, with estimates ranging from $4.74 billion to $4.80 billion. For the next financial year, analysts expect that the company will post sales of $5.01 billion per share, with estimates ranging from $4.96 billion to $5.04 billion. Zacks Investment Research's sales calculations are an average based on a survey of research firms that cover AMETEK. Get AMETEK alerts:
AMETEK (NYSE:AME) last posted its earnings results on Tuesday, July 31st. The technology company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.78 by $0.05. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. AMETEK had a net margin of 16.65% and a return on equity of 16.94%. AMETEK's revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the firm posted $0.65 earnings per share.
Several research firms have commented on AME. Cowen reaffirmed a "buy" rating and set a $85.00 price objective on shares of AMETEK in a research note on Sunday, August 12th. ValuEngine raised shares of AMETEK from a "hold" rating to a "buy" rating in a research note on Thursday, August 2nd. Oppenheimer lifted their price objective on shares of AMETEK from $85.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 1st. Bank of America lifted their price objective on shares of AMETEK from $87.00 to $91.00 and gave the stock a "buy" rating in a research note on Wednesday, August 1st. Finally, BMO Capital Markets lifted their price objective on shares of AMETEK from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 1st. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. AMETEK has a consensus rating of "Buy" and a consensus target price of $86.08.
NYSE AME opened at $75.73 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.71 and a debt-to-equity ratio of 0.42. The firm has a market cap of $17.60 billion, a price-to-earnings ratio of 29.02, a PEG ratio of 2.16 and a beta of 1.26. AMETEK has a 52 week low of $61.77 and a 52 week high of $79.32.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 14th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend is Thursday, September 13th. AMETEK's payout ratio is 21.46%.
In other news, Director Elizebeth R. Varet sold 3,000 shares of the business's stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $76.95, for a total transaction of $230,850.00. Following the completion of the sale, the director now directly owns 113,810 shares of the company's stock, valued at $8,757,679.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director Elizebeth R. Varet sold 2,000 shares of the business's stock in a transaction on Friday, June 8th. The shares were sold at an average price of $75.56, for a total transaction of $151,120.00. Following the sale, the director now directly owns 113,810 shares of the company's stock, valued at $8,599,483.60. The disclosure for this sale can be found here . Insiders have sold 12,000 shares of company stock valued at $905,480 over the last three months. Insiders own 2.00% of the company's stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of AMETEK by 1.0% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 73,586 shares of the technology company's stock valued at $5,310,000 after purchasing an additional 702 shares during the period. Elk Creek Partners LLC boosted its stake in shares of AMETEK by 17.1% during the first quarter. Elk Creek Partners LLC now owns 5,061 shares of the technology company's stock valued at $384,000 after purchasing an additional 739 shares during the period. BB&T Securities LLC boosted its stake in shares of AMETEK by 10.9% during the second quarter. BB&T Securities LLC now owns 7,908 shares of the technology company's stock valued at $570,000 after purchasing an additional 779 shares during the period. Riverhead Capital Management LLC boosted its stake in shares of AMETEK by 9.9% during the second quarter. Riverhead Capital Management LLC now owns 9,293 shares of the technology company's stock valued at $670,000 after purchasing an additional 836 shares during the period. Finally, Dean Capital Investments Management LLC boosted its stake in shares of AMETEK by 27.5% during the first quarter. Dean Capital Investments Management LLC now owns 3,928 shares of the technology company's stock valued at $298,000 after purchasing an additional 848 shares during the period. 84.19% of the stock is owned by hedge funds and other institutional investors.
AMETEK Company Profile
AMETEK, Inc manufactures and sells electronic instruments and electromechanical devices worldwide. Its Electronic Instruments Group segment offers advanced instruments for the process, power and industrial, and aerospace markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage markets; and instruments for the laboratory equipment, ultraprecision manufacturing, medical, and test and measurement markets.
Get a free copy of the Zacks research report on AMETEK (AME)
For more information about research offerings from Zacks Investment Research, visit Zacks.com AMETEK AMETE